Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 8/20 | 0.68 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.68 |
| ▸ | AKR1C1 | Q04828 | 6/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | AKR1C2 | P52895 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3802491 | 1.00 | AKR1C3 (0.68) | AKR1C3PTGS2AKR1C1POLBMAPT | |
| SCHEMBL3802490 | 1.00 | AKR1C3 (0.68) | AKR1C3PTGS2AKR1C1POLBMAPT | |
| SCHEMBL28931332 | 0.91 | PTGS2 (0.73) | AKR1C3PTGS2AKR1C1POLBAKR1C2 | |
| SCHEMBL9125567 | 0.86 | AKR1C1 (0.75) | AKR1C3PTGS2AKR1C1POLBMAPT | |
| SCHEMBL9125576 | 0.86 | AKR1C1 (0.75) | AKR1C3PTGS2AKR1C1POLBMAPT | |
| SCHEMBL3797590 | 0.85 | PTGS2 (0.57) | AKR1C3PTGS2AKR1C1POLBMAPT | |
| SCHEMBL3797595 | 0.85 | PTGS2 (0.57) | AKR1C3PTGS2AKR1C1POLBMAPT | |
| SCHEMBL5800288 | 0.85 | ALDH1A1 (0.71) | AKR1C3PTGS2AKR1C1POLBAKR1C2 | |
| SCHEMBL6384205 | 0.84 | AKR1C1 (0.78) | AKR1C3PTGS2AKR1C1POLBMAPT | |
| SCHEMBL13092046 | 0.84 | AKR1C1 (0.78) | AKR1C3PTGS2AKR1C1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718682-B2 | Heterocyclic analogs of diphenylethylene compounds | THERACOS, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-7718682-B2 | Heterocyclic analogs of diphenylethylene compounds | THERACOS, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-20080293949-A1 | Novel heterocyclic analogs of diphenylethylene compounds | THERACOS, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080293949-A1 | Novel heterocyclic analogs of diphenylethylene compounds | THERACOS, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| US-7407978-B2 | Heterocyclic analogs of diphenylethylene compounds | THERACOS, INC. (US) | 2008-08-05 | — | — | US | disclosed |
| US-7407978-B2 | Heterocyclic analogs of diphenylethylene compounds | THERACOS, INC. (US) | 2008-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293949-A1 | Novel heterocyclic analogs of diphenylethylene compounds | FFAR2, FFAR4, GPR119 | AKR1C3 1902/4885PTGS2 63/4885AKR1C1 1751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.